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Introduction DMD # 74500 8 until analysis of both free and total NPX concentrations. Preliminary studies showed that there was negligible nonspecific binding of NPX to the ultrafiltration device.
Drug Analysis.
The NPX concentrations in all samples were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Briefly, plasma samples (15 μL) from the PK and protein binding studies were spiked with 10 μL of IS working solutions (2.5 μg/mL) followed by precipitation with 400 μL of acetonitrile containing 0.1% of formic acid. The mixtures were vortexed for 1 min and sonicated for 20 s, then vortexed for another 10 s after sonication and centrifuged at 13000 ×g for 10 min. Then 300 μL of the supernatant were transferred to a 2-mL tube containing 1.2 mL of water and vortexed for 10 s. Finally, 10 μL of the mixture were injected onto the LC-MS/MS for analysis.
The NPX concentrations in the filtrates (free drug concentrations) from the protein binding studies were pretreated using the same method as plasma samples with slight modifications. Briefly, 75 μL of each filtrate sample was spiked with 10 μL of IS working solutions (2.5 μg/mL) followed by precipitation with 300 μL of acetonitrile containing 0.1% of formic acid. The remaining sample preparation procedures were as described above for the plasma samples.
The LC-MS/MS system consisted of a Shimadzu HPLC module including a binary pump, a degasser, an auto-sampler and a column oven (Kyoto, Japan), and an Applied Biosystems PE/Sciex API3000 mass spectrometer equipped with a turbo ion spray interface (Foster City, CA). Sample separations were achieved on a Targa C18 Column (particle size 5 μm, 100 × 2.1 mm; Higgins Analytical Inc., Mountain View, CA). The mobile phase consisted of eluent A (water/acetonitrile (95:5 v/v) containing 0.1% acetic acid) and eluent B (acetonitrile/water (95:5 v/v) containing 0.1% acetic acid) and was pumped at a flow rate of 0.23 mL/min with a gradient elution. The gradient profile was as follows: 0-4 min, 50% B;
a linear increase to 95% B from 4 to 6.5 min; a linear decrease to 50% B over 0.1 min; 50% B for 4.4 min;
and stop at 11.00 min. The auto-sampler was maintained at 4°C during the run. The mass spectrometer was operated in the negative ionization mode for the detection of ion transitions at m/z 229.2/169.9 for NPX and 232.0/169.9 for IS. The system was controlled by Analyst software version 1.4 (Applied Biosystems SciEx) for data acquisition and analysis.
This article has not been copyedited and formatted. The final version may differ from this version. Linearity was found over the concentration ranges of 0.125 to 40 µg/mL for plasma and 0.01 to 30 µg/mL for filtrate samples. The coefficient of variation (CV%) of intra-and inter-day accuracies and precisions were all with CV% <10%. The recovery of the sample preparation method approached 100%.
Naproxen in rat plasma was previously found to be stable under various conditions (Shi et al., 2015) .
Protein Binding and Pharmacokinetic Data Analysis. The binding capacity and association constants were estimated by fitting the bound versus free drug concentrations using an equation describing two classes of binding sites (Wong et al., 1999) :
where and are the bound and free plasma NPX concentrations; Ka 1 and Ka 2 are the association constants for the first and second class of binding sites; n 1 and n 2 are the numbers of first and second class binding sites; and Pt is the albumin concentration in plasma.
The relationship between bound and total drug concentrations is:
where is the total plasma concentration of NPX.
Based on the assessment of the plasma protein binding data, • ≪ 1, and substitution for bound concentrations using equation (2) yields:
where there is one positive root for free drug concentration:
The protein binding of NPX in tissues is considered to occur primarily to albumin in the interstitial fluid (ISF) (Aukland and Nicolaysen, 1981; Rodgers and Rowland, 2006 relationship between total (C t ) and unbound tissue concentrations (C ut ) of NPX could also be described by Eq. (4) with a difference in ISF and plasma protein concentrations where Pt is multiplied by E/P, the ratio of protein concentrations in ISF and plasma.
According to the "Free Hormone Hypothesis" (Mendel, 1989) , disposition processes often operate only on free drug. Therefore, NPX plasma concentration-time profiles were characterized by compartment models based on free drug concentrations with binding calculated from total concentrations. Several models including one-and two-compartment PK models (with or without an absorption process) with binding were tested, and the final PK model selected ( Figure 1 ) was a two-compartment model with first-order absorption process incorporating nonlinear protein binding. The final PK model equations and initial conditions are:
where A a indicates the amount of NPX at the absorption site, k a is the first-order absorption rate constant, CL and CL d are the plasma and distribution clearances of unbound NPX, V p and V t are the volumes of distribution of total NPX in central and peripheral compartments, and F is the bioavailability of the IP dose calculated to be about 0.9 from literature-reported IV data in rats (Lauroba et al., 1986) . The drug was given IP to minimize stress in the animals and based on observations that NPX absorption is rapid, reproducible, and essentially complete by this route (Huntjens et al, 2006) .
Initial non-compartmental analysis (NCA) of the PK data was performed using the Phoenix The variance model used was: 
Results
Quantification of Plasma Albumin. An anti-rat albumin ELISA was applied to determine whether sex and the presence of arthritis influence the plasma concentrations of albumin. As shown in both Figure 2 and Table 1 , the plasma albumin concentrations in CIA rats were significantly lower than those in healthy animals, consistent with the situation in humans that hypoalbuminemia is a feature of RA (Wilkinson et al., 1965) . It is interesting to note that albumin concentrations also differed significantly with sex in rats with lower values observed in males.
Protein Binding of NPX. Protein binding studies of NPX were carried out using plasma from the four animal groups. Plasma protein binding of NPX in rats showed concentration-dependence, with higher unbound fractions at higher total plasma concentrations ( Figure 3 ). Higher percent binding of NPX to rat plasma proteins (> 93%) was observed at normal therapeutic concentrations in all groups with very small variation (CV% < 2.36%). However, a significant decrease in binding was found at total concentrations greater than 50 µg/mL in CIA rats and above 100 µg/mL in healthy rats (Supplemental Table S1 ). Rosenthal 1) (Supplemental model code for protein binding). Preliminary fittings allowing n 1 and n 2 to vary yielded the nearest integers of 1 and 4, which were then fixed for subsequent assessment. As shown in Figure 4 , there was a very good agreement between the observed and fitted data except that the bound concentrations in CIA males were slightly under predicted at the highest free concentrations. The association constants listed in Table 2 indicate that NPX is bound to rat plasma albumin with high affinity, and the first class (n 1 ) of binding sites differed from the second (n 2 ) as Ka 2 was only about 2% of Ka 1 . In addition, the binding capacities (nPt) varied with lower binding capacities in the CIA rats and male rats ( Table 1) .
Pharmacokinetics of NPX.
The PK of NPX was investigated in CIA rats and compared with that in healthy animals. Following IP doses of NPX (10, 25 and 50 mg/kg) to CIA rats and 50 mg/kg to healthy rats, the NPX PK profiles of all groups shown in Figures 5 and 6 were bi-exponential with parallel
This article has not been copyedited and formatted. The final version may differ from this version. elimination phases between the dose groups. A sharper initial decline was observed in higher dose groups, indicating that distribution rates increased with dose/concentration. The primary PK parameters for total drug were initially calculated by NCA for comparison with published PK results. In CIA rats, plasma NPX concentrations increased less than dose-proportionally in both sex groups, as indicated by the dosenormalized AUC, which decreased by nearly 2-fold over the 5-fold range of doses. In addition, the apparent volume of distribution (V/F) and apparent clearance (CL/F) significantly increased in the highest dose groups (50 mg/kg) compared to those in the 10 mg/kg dose groups (Table 3) . Together, these results indicated the occurrence of dose-dependent PK of NPX in CIA rats. The NCA results for arthritic and healthy rats are listed in Table 4 . The AUC of total NPX in arthritic rats was significantly lower than that in healthy animals. Both V/F and CL/F values in CIA rats were about 30-50% higher than the corresponding values in healthy rats. Despite these differences, NCA did not indicate any significant differences in the PK parameters between female and male rats. In addition, the terminal half-life (t 1/2 ) was similar in all dose groups in CIA rats and between arthritic and healthy rats at the same dose level (Tables 2 and 3 ). The apparent clearance values for NPX are considerably smaller than hepatic plasma flow (circa 1200 ml/h/kg) (Davies and Morris, 1993) indicating that this is a low clearance compound and should have little first-pass loss after IP administration.
A two-compartment model with a first-order absorption process and nonlinear albumin binding ( Figure 1 ) was used to describe the PK of NPX (Supplemental model code for PK estimation). Free NPX concentrations calculated from the total using the protein binding parameters in Table 1 (Simkin, 1979; Wallis et al., 1985; Day et al., 1999) .
It is apparent that NPX is a low extraction drug and its unbound plasma clearance is mainly determined by the intrinsic clearance based on the well-stirred model of hepatic clearance. The unbound plasma NPX concentration-time profiles for all 50 mg/kg dose groups are shown in Figure 7 . In both sex groups, arthritic rats showed higher peak unbound concentrations (13.52 vs. 8.14 µg/mL for females and 13.51 vs. 
Discussion
Protein binding has been known play a substantial role in the PK and PD of NSAIDs (Lin et al., 1987) . NPX is an acidic NSAID that is extensively bound to albumin (>99%) within the normal therapeutic range in plasma (20~200 µg/mL) (Mortensen et al., 1979) . Different plasma albumin concentrations and binding kinetics of NPX with disease and sex, along with altered intrinsic clearances affected the disposition of NPX.
We found lower albumin concentrations along with nonlinear NPX PK in arthritic rats producing a disproportionate increase of AUC with dose. This phenomenon occurs in humans, where the AUC of NPX tended to plateau at higher doses (500 to 900 mg, which are about 45 to 80 mg/kg in rats) (Runkel et al., 1974) . The absorption of NPX is rapid and complete (Runkel et al., 1974; Segre, 1975) and NPX absorption in RA patients is similar to healthy subjects (van den Ouweland et al., 1987; Vree et al., 1993) .
Therefore, the explanation for the plateau effect in AUC was a greater clearance at high doses due to elevated free drug concentrations resulting from saturation of albumin binding (Mortensen et al., 1979; Calvo and Dominguezgil, 1983) . Under inflammatory conditions, albumin is also subject to increased catabolism (Wilkinson et al., 1965) . Altered albumin binding in RA results in more free drug available for elimination, leading to lower AUC and higher CL in both RA patients and CIA rats given the same dose levels. Thus, different PK behaviors were expected between healthy and arthritic rats, in accordance with findings in humans (van den Ouweland et al., 1987) . Although t 1/2 did not change with dose or disease, this parameter was determined by concentrations falling within the linear protein binding range.
As seen from the ELISA results, plasma albumin concentrations differed significantly with disease and sex with lower values in CIA rats and in male rats. A negative correlation was found between the NCA values of CL/F and plasma albumin concentrations in all groups (r = 0.94), and the values of V/F in both sex groups were also inversely related to plasma albumin concentrations. These results confirmed that chronic inflammation reduced plasma albumin and partly influenced the PK of NPX. However, different albumin concentrations between female and male rats did not produce differences in PK, suggesting that other factors (e.g. drug metabolism) are involved. This study was enacted to further explore and comprehensively integrate and model the role of different plasma albumin concentrations on the binding of NPX, to examine whether nonlinear protein binding accounts for the nonlinearities in NPX PK, and assess disease and sex effects. The bound fractions of NPX in our study are slightly higher than other data in rats (Huntjens et al., 2006) . In our study, protein binding of NPX was constant at low drug concentrations and became saturated at higher concentrations.
Such saturation of binding was observed at lower NPX concentrations in CIA rats, which can be explained by their lower albumin concentrations. In CIA rats, even with very small decreases in percent bound, the unbound fractions of NPX can vary up to about 6-fold over the therapeutic concentration range, which is comparable to the situation in humans (Borga and Borga, 1997). Our companion study assesses whether the pharmacological effects of NPX can be directly related to the unbound drug concentrations in CIA rats (Li et al, 2017) .
Initial modeling tests showed that the estimated number of binding sites n 1 and n 2 were close to 1 and 4, in all groups except CIA males where the estimated n 2 value was 6.6. Nonetheless, uniform values of n (n 1 =1 and n 2 =4) were chosen for all groups in the final model and only the association constants (Ka 1
and Ka 2 ) were estimated. The binding affinity of NPX to one class of binding site on albumin was much higher than the other. Attempted modeling of all protein binding data using single values for Ka 1 and Ka 2 produced less satisfactory overall fittings. The lower binding capacity observed in CIA rats and in male rats was primarily due to their lower albumin concentrations.
From the perspective of mechanism, albumin and drug concentration-dependent protein binding was incorporated into a classic type of 2CM to account for the nonlinearity of NPX PK. This modeling approach is based on the literature (Fleishaker and McNamara, 1985) in that free drug was used to govern the distribution process of total drug. However, their model only applies when protein binding and clearance are linear. Our model is more comprehensive in accounting for nonlinear binding in plasma and tissues, operating both distribution and elimination processes using unbound drug, and featuring a global analysis of all experimental data jointly. These advantages offset our ability to capture all data perfectly, especially the last time point, which differs from the fitting trend for unknown reasons.
This article has not been copyedited and formatted. The final version may differ from this version. Protein concentrations in tissue interstitial space are known to increase due to the increase of microvascular permeability with inflammation (Aukland and Johnsen, 1974; Simkin, 1979; Bell et al., 1983) ; therefore, different E/P values were assigned to CIA and healthy rats. The average E/P based on the literature is about 0.5 for healthy rats (Rodgers et al., 2005; Rodgers and Rowland, 2006) . Assuming that increased albumin concentrations in CIA ISF is mainly attributed to the transfer of albumin from plasma to ISF, the E/P value used for CIA rats was about 0.9 based on the reduced fraction of plasma albumin concentrations. This is in accordance with findings in humans that E/P is about 0.32 in healthy subjects and increases to about 0.73 in RA patients (Fleishaker and McNamara, 1985; Day et al., 1995) . Since no significant alteration of the absorption of NPX occurs with RA (van den Ouweland et al., 1987; Vree et al., 1993) , the absorption rate constant (k a ) was shared for all groups. The central distribution volume of total drug (V p ) was difficult to estimate perhaps owing to the IP doses and thus it was fixed to rat plasma volume to improve model stability. In the final model, different values of unbound plasma clearances (CL), unbound distribution clearances (CL d ) and peripheral distribution volumes of total drug (V t ) were assigned for CIA and healthy rats. The presence of pro-inflammatory mediators during inflammation is commonly associated with reduced CYP expression and activity, leading to impaired drug metabolism (Slaviero et al., 2003; Renton, 2005) . Therefore, the lower value of CL Arthritic was expected as NPX undergoes significant hepatic metabolism that is primarily dependent on cytochromes CYP2C9 and CYP1A2 (Miners et al., 1996) . The effects of chronic inflammation on the tissue disposition of NPX still remain unclear. However, it might be anticipated that the diffusion of unbound NPX into and out of tissues should decrease due to decreased perfusion with inflammation (Wallis et al., 1985) . The lower unbound distribution clearance observed in CIA rats is consistent with this. The larger peripheral distribution volume of total NPX in CIA rats corresponded well with the NCA results. As the ISF protein concentrations increase with inflammation, the bound fraction of NPX will increase in ISF and thereby enhance the penetration of total drug into tissue as previously reported (Fleishaker and McNamara, 1985) . The estimated V t values of all groups were smaller than ISF volume, which might be due to collagen occupying part of the ISF space. The PK parameters based on free drug were independent of dose confirming that saturation of protein binding was the major determinant of the dose-dependent PK in CIA rats. Despite the consistency of findings regarding the influences of RA on the disposition of total and unbound NPX, our results showed no significant sex effects.
It was reported that females exhibited higher free NPX concentrations than male patients with osteoarthritis (Hundal et al., 1991) .
The CIA rat model exhibits many similar histopathological features as human RA such as synovial proliferation, pannus formation, and cartilage destruction (Stuart et al., 1982) . Therefore, the results of this study appear to mimic and explain the nonlinear PK of NPX in humans, as well as the effects of chronic inflammation and sex on the protein binding and disposition of NPX in RA patients.
In conclusion, plasma albumin concentrations in rats differed significantly with sex and arthritis, which leads to markedly different PK behaviors of NPX. Reduced albumin in plasma and altered protein binding of NPX was shown to be the primary cause for the dose-dependent PK of NPX in normal and arthritic rats, with the latter also exhibiting impaired clearance of free drug. The PK profiles of NPX in all groups were well-described by the global PK model incorporating these diverse factors. This is the most complete exploration of the nonlinear PK of NPX with comparisons based on sex and presence of disease.
This study serves as the prelude for our subsequent pharmacodynamics study of NPX in CIA rats (Li et al, 2017 ).
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